真实世界自对照病例系列评估临床试验入选标准对重症哮喘生物制剂疗效的影响
基于CHRONICLE前瞻性队列中480例美国重症哮喘成人患者,采用自对照病例系列分析生物制剂暴露期与未暴露期的急性发作率,并与六项随机对照试验的荟萃分析比较。生物制剂在真实世界中降低急性发作率(IRR 0.43,95%CI 0.39–0.48),且吸烟史、急性发作史、呼出气一氧化氮分数和血嗜酸性粒细胞计数标准存在显著效应修饰。
要点
- 生物制剂在真实世界重症哮喘患者中显著降低急性发作率,与RCT荟萃分析结果一致。
- 吸烟史少、急性发作史多、呼出气一氧化氮分数高和血嗜酸性粒细胞计数高的人群从生物制剂中获益更明显。
- 基于COPD、支气管扩张或FEV1的排除标准对疗效影响不显著,但可能过度限制人群代表性。
核心结论
- 基于2型生物标志物升高、吸烟史少和急性发作史的标准可富集可能从生物制剂中获益的试验人群。
- 基于肺功能检查的排除标准对治疗反应影响有限,但可能不当限制研究结果的普适性。
研究设计与样本
- CHRONICLE为美国多中心、前瞻性、非干预性成人(≥18岁)重症哮喘队列(NCT03373045)。
- 采用自对照病例系列分析生物制剂暴露期与未暴露期的重症哮喘急性发作率,并与六项RCT的荟萃分析比较。
- 亚组分析评估九项RCT来源标准下纳入与排除组间的效应修饰。
主要发现
- RCT荟萃分析中生物制剂降低急性发作率(率比0.53,95%CI 0.47–0.60)。
- 真实世界自对照病例系列中生物制剂降低急性发作率(IRR 0.43,95%CI 0.39–0.48)。
- 吸烟史标准存在显著效应修饰(比值比0.50,95%CI 0.38–0.66,以排除组为参照)。
- 急性发作史标准存在显著效应修饰(比值比0.49,95%CI 0.36–0.65,以排除组为参照)。
- 呼出气一氧化氮分数标准存在显著效应修饰(比值比0.63,95%CI 0.42–0.92,以排除组为参照)。
临床怎么用
- 临床选择生物制剂时,可优先考虑吸烟史少、急性发作史多、呼出气一氧化氮分数高或血嗜酸性粒细胞计数高的重症哮喘患者。
- 基于COPD、支气管扩张或FEV1的排除标准不应过度限制生物制剂在真实世界中的适用人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The trade-offs between regulatory preferences, trial success probability, and patient exclusion by eligibility criteria in randomised controlled trials (RCTs) of biologics for severe asthma remain poorly understood. We assessed biologic effectiveness and effect modification by nine RCT-derived criteria in a large real-world cohort of subspecialist-treated patients with severe asthma. METHODS: CHRONICLE was a multicentre, prospective, noninterventional cohort of adults (aged ≥18 years) in the United States of America with severe asthma (ClinicalTrials.gov identifier NCT03373045). We performed a meta-analysis of six RCTs to estimate pooled rate ratios for United States Food and Drug Administration approved biologics and compared with incidence rate ratios (IRRs) from a self-controlled case-series using CHRONICLE data, analysing severe asthma exacerbation rates during biologic-exposed and unexposed periods. Subgroup analyses examined between-group comparisons (inclusion versus exclusion) across nine RCT-based criteria. FINDINGS: Biologics reduced exacerbation rates in both RCT meta-analysis (rate ratio 0.53, 95% CI 0.47-0.60) and real-world self-controlled case-series of 480 patients from 85 sites (enrolled between 28 February 2018 and 28 October 2024) (IRR 0.43, 95% CI 0.39-0.48). Significant effect modification (ratio of ratios, ratio of IRR (95% CI), with exclusion as the reference) was observed for smoking history (0.50, 0.38-0.66), exacerbation history (0.49, 0.36-0.65), exhaled nitric oxide fraction (0.63, 0.42-0.92), and blood eosinophil count (0.65, 0.51-0.82). No significant differences were observed for COPD, bronchiectasis, or forced expiratory volume in 1 s based criteria, which excluded the most patients in the cohort. INTERPRETATION: Criteria based on elevated type 2 biomarkers, minimal smoking, and exacerbation history enrich trial populations likely to benefit from biologics. Spirometry-based exclusions appear to have limited influence on treatment response, and there is a risk that they unduly restrict generalisability.
引用
- Boakye-Dankwa, Kiddle, Koo, et al. A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE study. Eur Respir J. 2026. PMID: 42242757. doi:10.1183/13993003.02196-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。